| __timestamp | Apellis Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 660772000 |
| Thursday, January 1, 2015 | 6356782 | 736435000 |
| Friday, January 1, 2016 | 4303743 | 775266000 |
| Sunday, January 1, 2017 | 10463151 | 860348000 |
| Monday, January 1, 2018 | 22639184 | 814775000 |
| Tuesday, January 1, 2019 | 67046483 | 942821000 |
| Wednesday, January 1, 2020 | 139401000 | 985616000 |
| Friday, January 1, 2021 | 176771000 | 1061508000 |
| Saturday, January 1, 2022 | 277163000 | 1190423000 |
| Sunday, January 1, 2023 | 500815000 | 1254234000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Grifols, S.A. and Apellis Pharmaceuticals, Inc., from 2014 to 2023. Over this period, Grifols consistently outspent Apellis, with SG&A expenses peaking at approximately 1.25 billion in 2023, a 90% increase from 2014. In contrast, Apellis saw a dramatic rise in its SG&A expenses, surging from a modest 2.9 million in 2014 to over 500 million in 2023, marking an exponential growth of over 17,000%. This stark contrast highlights Grifols' established market presence and Apellis' rapid expansion strategy. Understanding these trends provides valuable insights into each company's operational strategies and market positioning.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Cytokinetics, Incorporated
Grifols, S.A. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Grifols, S.A. and Geron Corporation
Grifols, S.A. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.